Aging and Alzheimer's disease: protease inhibitors in cerebrospinal fluid.
Recent advances suggested that proteases and their inhibitors could be implicated in the genesis and/or maturation of insoluble deposits associated with Alzheimer's disease (AD). This study was designed to measure the level of alpha 1-antichymotrypsin (ACT) and alpha 1-antitrypsin (AT) in cerebrospinal fluid (CSF) of patients with AD and nondemented humans at various ages. Our analysis failed to demonstrate a significant relationship between inhibitor content and disease. However, a positive correlation was observed between age and the ACT level for the normal control group. Such observation suggests a specific association of ACT with the mechanisms of brain aging.
Delamarche
C
C
INSERM U 298, Centre Hospitalier Regional, Angers, France.
Berger
F
F
Gallard
L
L
Pouplard-Barthelaix
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000097:blood / Q000134:cerebrospinal fluid*; D000544:Alzheimer Disease / Q000097:blood / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000514:alpha 1-Antichymotrypsin / Q000097:blood / Q000134:cerebrospinal fluid*; D000515:alpha 1-Antitrypsin / Q000134:cerebrospinal fluid* / Q000378:metabolism
D000514:alpha 1-Antichymotrypsin; D000515:alpha 1-Antitrypsin